Pulmonary function alterations after induction therapy for lung cancer: Preoperative considerations

Gabriel Loor, Mark K. Ferguson

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


Neoadjuvant chemotherapy or chemoradiotherapy prior to surgery offers hope for extended survival in patients with regionally advanced non-small cell lung cancer (NSCLC), particularly those patients with ipsilateral mediastinal nodal involvement. However, neoadjuvant therapies are sometimes associated with pulmonary toxicity. A recent large scale analysis using the Society of Thoracic Surgery (STS) General Thoracic Surgery Database identified induction therapy as an independent predictor of postoperative pulmonary complications.1 The present chapter reviews the effects of neoadjuvant therapy on pulmonary function as well as perioperative morbidity and mortality, and examines whether altering the timing of resection can reduce the risk of complications.

Original languageEnglish (US)
Title of host publicationDifficult Decisions in Thoracic Surgery (Second Edition)
Subtitle of host publicationAn Evidence-Based Approach
PublisherSpringer London
Number of pages6
ISBN (Print)9781849963640
StatePublished - Dec 1 2011


Dive into the research topics of 'Pulmonary function alterations after induction therapy for lung cancer: Preoperative considerations'. Together they form a unique fingerprint.

Cite this